Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

SciClone Acquires China Rights for PAD Drug from Taiwan Liposome

publication date: Jun 26, 2013
SciClone Pharma, a US company that brings western-style drugs to China, has licensed exclusive rights to a treatment for peripheral arterial disease from Taiwan Liposome Company (TLC). The product, called ProFlow®, is a novel lipid formulation of prostaglandin E1 (PGE1), a vasodilator and platelet inhibitor. The agreement calls for up to $39.5 million in development and sales milestones. More details....

Stock Symbol: (NSDQ: SCLN)

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital